Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$28.81
-0.1%
$29.98
$22.90
$36.45
$4.75B0.471.73 million shs2.94 million shs
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
$9.09
$9.06
$4.01
$9.10
$1.20B0.834.50 million shsN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.32
+0.1%
$12.39
$8.02
$15.78
$7.10B1.675.10 million shs5.61 million shs
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$39.80
+0.1%
$33.97
$23.95
$52.34
$6.33B0.181.59 million shs2.48 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
0.00%-0.96%-4.76%-13.25%+17.26%
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
0.00%0.00%0.00%0.00%0.00%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%+6.32%+5.88%+37.71%-20.34%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
0.00%+6.39%+18.95%+27.77%-16.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alkermes plc stock logo
ALKS
Alkermes
4.9026 of 5 stars
4.43.00.04.22.92.51.9
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.1281 of 5 stars
1.34.00.00.31.31.71.3
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
4.4671 of 5 stars
4.42.00.03.01.93.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.83
Moderate Buy$40.0038.84% Upside
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
0.00
N/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.50
Moderate Buy$15.175.95% Upside
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.72
Moderate Buy$57.8845.41% Upside

Current Analyst Ratings Breakdown

Latest CTIC, ELAN, IONS, and ALKS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/26/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
6/17/2025
Alkermes plc stock logo
ALKS
Alkermes
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$33.00 ➝ $42.00
6/12/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$45.00 ➝ $48.00
5/28/2025
Alkermes plc stock logo
ALKS
Alkermes
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral ➝ Buy$45.00
5/20/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/13/2025
Alkermes plc stock logo
ALKS
Alkermes
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
5/2/2025
Alkermes plc stock logo
ALKS
Alkermes
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/2/2025
Alkermes plc stock logo
ALKS
Alkermes
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.00
(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.56B3.05$2.65 per share10.87$9.05 per share3.18
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
$53M22.62N/AN/A($0.14) per share-64.93
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.60$2.26 per share6.34$12.33 per share1.16
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$705M8.99N/AN/A$3.73 per share10.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$367.07M$2.0913.7821.031.7923.30%27.52%17.98%7/23/2025 (Estimated)
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7419.3416.082.808.43%7.54%3.57%8/6/2025 (Estimated)
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)

Latest CTIC, ELAN, IONS, and ALKS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.42N/AN/AN/A$343.20 millionN/A
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/1/2025Q1 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.32$0.13-$0.19$0.13$307.53 million$306.51 million
4/30/2025Q1 2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
N/A
3.33
2.92
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/A
1.27
1.26
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.63
9.66
9.62

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
91.45%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
93.86%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.40%
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
7.61%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
1,800164.90 million157.65 millionOptionable
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
127131.88 million121.84 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1,069159.16 million155.02 millionOptionable

Recent News About These Companies

IONS - Ionis Pharmaceuticals Inc Sustainability - Morningstar
Salanersen shines in early spinal muscular atrophy research

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alkermes stock logo

Alkermes NASDAQ:ALKS

$28.81 -0.02 (-0.07%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$29.10 +0.29 (+1.02%)
As of 06/27/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

CTI BioPharma stock logo

CTI BioPharma NASDAQ:CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.32 +0.02 (+0.10%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$14.28 -0.04 (-0.24%)
As of 06/27/2025 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Ionis Pharmaceuticals stock logo

Ionis Pharmaceuticals NASDAQ:IONS

$39.80 +0.02 (+0.05%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$40.14 +0.34 (+0.85%)
As of 06/27/2025 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.